Hantavirus-related biotech stocks rise 15% in 6 months

The absence of cases reduces near-term market demand for treatments. However, biotech firms with hantavirus-focused pipelines may see speculative buying if a major outbreak risk is perceived in another region.

Implied probability (Yes)

60%